• Earlier this week, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion backing Gilead Sciences’ Trodelvy in combination with Merck’s Keytruda as a first-line treatment for certain adults with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score of at least 10.
• This recommendation, grounded in Phase 3 ASCENT-04/KEYNOTE-D19 data showing a materially lower risk of disease progression or death versus chemotherapy plus Keytruda, highlights Trodelvy’s growing role in addressing one of the hardest-to-treat forms of breast cancer.
• We’ll now explore how this positive CHMP opinion for first-line Trodelvy plus Keytruda may influence Gilead’s oncology-led investment narrative.

Find 48 companies with promising cash flow potential yet trading below their fair value.

Gilead Sciences Investment Narrative Recap

To own Gilead, you generally need to believe its HIV cash flows can fund a meaningful second growth engine in oncology, with Trodelvy at the center. The CHMP’s positive opinion for Trodelvy plus Keytruda in first-line PD-L1 positive TNBC supports that oncology narrative, but the most important short term catalyst still looks like execution across broader Trodelvy indications, while the biggest risk remains whether new launches can offset future patent and pricing pressures in HIV.

Among recent developments, the mixed sentiment around Gilead’s upcoming August 4 earnings is particularly relevant. Consensus expects higher revenue but lower earnings, underscoring how expensive oncology and pipeline build-out can be in the near term. For investors watching Trodelvy, this earnings update may help clarify how much oncology is already contributing and how management is balancing R&D spending with the need to sustain margins while advancing programs like Trodelvy plus Keytruda.

But while Trodelvy is gaining clinical momentum, investors should also be aware that pricing pressure and pipeline execution risk could still...

Gilead Sciences' narrative projects $34.5 billion revenue and $10.8 billion earnings by 2029.

Uncover how Gilead Sciences' forecasts yield a $157.83 fair value, a 19% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling revenue of about US$38.1 billion and earnings of roughly US$12.7 billion by 2029, which is far more upbeat than consensus and leans heavily on Trodelvy and lenacapavir success, so this new breast cancer news may either reinforce that bullish view or prompt you to reconsider how much risk you think sits in Gilead’s pipeline story.

Explore 5 other fair value estimates on Gilead Sciences - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Gilead Sciences research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Gilead Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Gilead Sciences' overall financial health at a glance.

Ready For A Different Approach?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.